SAM
VRTX icon

Silvercrest Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Silvercrest Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.3M Buy
16,358
+330
+2% +$154K 0.05% 369
2025
Q4 		$7.27M Sell
16,028
-931
-5% -$401K 0.05% 380
2025
Q3 		$6.64M Buy
16,959
+6
+0% +$2.51K 0.04% 386
2025
Q2 		$7.55M Buy
16,953
+107
+0.6% +$49.3K 0.05% 365
2025
Q1 		$8.17M Sell
16,846
-502
-3% -$234K 0.06% 329
2024
Q4 		$6.99M Buy
17,348
+3,410
+24% +$1.58M 0.05% 361
2024
Q3 		$6.48M Buy
13,938
+179
+1% +$86K 0.04% 338
2024
Q2 		$6.45M Hold
13,759
– – 0.04% 358
2024
Q1 		$5.75M Sell
13,759
-20
-0.1% -$8.46K 0.04% 367
2023
Q4 		$5.61M Sell
13,779
-473
-3% -$175K 0.04% 354
2023
Q3 		$4.96M Buy
14,252
+250
+2% +$87.4K 0.04% 361
2023
Q2 		$4.93M Buy
14,002
+583
+4% +$196K 0.04% 371
2023
Q1 		$4.23M Sell
13,419
-10
-0.1% -$3K 0.03% 378
2022
Q4 		$3.88M Sell
13,429
-49
-0.4% -$14.9K 0.03% 380
2022
Q3 		$3.9M Sell
13,478
-40
-0.3% -$11.5K 0.03% 365
2022
Q2 		$3.81M Sell
13,518
-558
-4% -$149K 0.03% 388
2022
Q1 		$3.67M Buy
14,076
+6
+0% +$1.42K 0.02% 418
2021
Q4 		$3.09M Hold
14,070
– – 0.02% 434
2021
Q3 		$2.55M Hold
14,070
– – 0.02% 468
2021
Q2 		$2.84M Hold
14,070
– – 0.02% 453
2021
Q1 		$3.02M Sell
14,070
-666
-5% -$146K 0.02% 441
2020
Q4 		$3.48M Buy
14,736
+700
+5% +$161K 0.03% 406
2020
Q3 		$3.82M Hold
14,036
– – 0.03% 379
2020
Q2 		$4.08M Hold
14,036
– – 0.04% 365
2020
Q1 		$3.34M Buy
14,036
+619
+5% +$142K 0.04% 352
2019
Q4 		$2.94M Hold
13,417
– – 0.02% 432
2019
Q3 		$2.27M Hold
13,417
– – 0.02% 455
2019
Q2 		$2.46M Buy
13,417
+1,793
+15% +$313K 0.02% 310
2019
Q1 		$2.14M Sell
11,624
-49
-0.4% -$9.05K 0.02% 317
2018
Q4 		$1.93M Buy
11,673
+49
+0.4% +$8.49K 0.02% 304
2018
Q3 		$2.24M Buy
11,624
+55
+0.5% +$9.79K 0.02% 311
2018
Q2 		$1.97M Buy
11,569
+1,779
+18% +$276K 0.02% 326
2018
Q1 		$1.6M Sell
9,790
-233
-2% -$38.1K 0.02% 334
2017
Q4 		$1.5M Buy
10,023
+43
+0.4% +$6.37K 0.01% 338
2017
Q3 		$1.52M Hold
9,980
– – 0.02% 328
2017
Q2 		$1.29M Buy
9,980
+3,291
+49% +$396K 0.01% 337
2017
Q1 		$731K Hold
6,689
– – 0.01% 377
2016
Q4 		$493K Hold
6,689
– – 0.01% 414
2016
Q3 		$583K Hold
6,689
– – 0.01% 391
2016
Q2 		$575K Sell
6,689
-150
-2% -$13K 0.01% 392
2016
Q1 		$544K Hold
6,839
– – 0.01% 397
2015
Q4 		$861K Sell
6,839
-125
-2% -$15.1K 0.01% 368
2015
Q3 		$725K Hold
6,964
– – 0.01% 348
2015
Q2 		$860K Buy
6,964
+600
+9% +$75.6K 0.01% 356
2015
Q1 		$751K Sell
6,364
-600
-9% -$71.9K 0.01% 338
2014
Q4 		$827K Buy
6,964
+750
+12% +$84.5K 0.01% 327
2014
Q3 		$698K Hold
6,214
– – 0.01% 338
2014
Q2 		$588K Sell
6,214
-400
-6% -$28K 0.01% 350
2014
Q1 		$468K Hold
6,614
– – 0.01% 349
2013
Q4 		$491K Hold
6,614
– – 0.01% 351
2013
Q3 		$501K Sell
6,614
-10
-0.2% -$796 0.01% 343
2013
Q2 		$530K Buy
+6,624
New +$488K 0.01% 326

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Silvercrest Asset Management's VRTX Position: Q1 2026 in Review

Silvercrest Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q1 2026, buying an estimated $154K and bringing the position to 16,358 shares worth $7.3M. The position accounts for 0.05% of the portfolio, ranked #369.

Silvercrest Asset Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.17M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Silvercrest Asset Management held 16,358 shares of Vertex Pharmaceuticals worth $7.3M as of Q1 2026.
  • Silvercrest Asset Management bought 330 Vertex Pharmaceuticals shares in Q1 2026, an estimated $154K.
  • Vertex Pharmaceuticals made up 0.05% of Silvercrest Asset Management's portfolio in Q1 2026, its #369 holding.
  • Silvercrest Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Silvercrest Asset Management's Vertex Pharmaceuticals position peaked at $8.17M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.